Metaio
Metaio was a privately held Augmented Reality (AR) company that developed software technology and provided services for the creation of AR applications and experiences. The company was founded in 2003 in Munich, Germany, by Thomas Alt and Peter Meier. Metaio's technology was used in more than 1,000 applications for enterprise, marketing, retail, publishing and industrial cases by over 140,000 developers.
History
Metaio was originally a subsidiary of the German automation company Volkswagen before becoming an independent firm in 2005. The company's initial focus was on research and development for industrial AR applications, but it later expanded into consumer-oriented applications.
In 2014, Metaio launched the first publicly available cloud-based system for AR, called Metaio Cloud. This platform allowed developers to create and manage AR experiences that could be accessed from any device.
In May 2015, Metaio was acquired by Apple, which subsequently discontinued the company's products and services. The technology and expertise acquired from Metaio have since been used in the development of Apple's ARKit, a framework for creating AR experiences on iOS devices.
Technology
Metaio's technology was based on a proprietary AR engine that could recognize, track and augment 2D images, 3D objects, and barcodes. The engine was compatible with a wide range of devices, including smartphones, tablets, and smart glasses.
The company also developed Metaio Creator, a software tool that allowed non-programmers to create AR experiences by dragging and dropping digital content onto images or 3D objects. This tool was used in various industries, including retail, marketing, and publishing.
Impact
Metaio played a significant role in the development and popularization of AR technology. The company's software was used in a variety of applications, from interactive marketing campaigns to industrial maintenance guides. Metaio's acquisition by Apple and the subsequent development of ARKit have also contributed to the growth of the AR industry.
See also
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
